Adamis Pharma's Tempol Decreases COVID-19 Related Lung Inflammation In Animal Studies

Adamis Pharmaceuticals Corp ADMP has reported positive data from lab studies conducted in animal models.

• The study showed that Tempol-treated hamsters challenged with COVID-19 infection achieved decreased inflammation in the lungs compared to controls.
• The group plans on submitting the publication to a peer-review journal.
• Recently, the FDA cleared Adamis to proceed with a Phase 2/3 study to examine the effects of Tempol on preventing COVID-19 related hospitalization.
• Price Action: ADMP shares are trading 9.6% higher at $1.14 in market trading hours on the last check Monday.